Compare IQ & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQ | TWST |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2018 | 2018 |
| Metric | IQ | TWST |
|---|---|---|
| Price | $2.02 | $40.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $2.87 | ★ $44.67 |
| AVG Volume (30 Days) | ★ 9.5M | 1.2M |
| Earning Date | 02-17-2026 | 02-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,808,085,043.00 | $376,572,000.00 |
| Revenue This Year | N/A | $15.19 |
| Revenue Next Year | $2.72 | $15.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.32 |
| 52 Week Low | $1.50 | $23.30 |
| 52 Week High | $2.84 | $55.33 |
| Indicator | IQ | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 69.80 |
| Support Level | $2.00 | $34.55 |
| Resistance Level | $2.14 | $41.34 |
| Average True Range (ATR) | 0.08 | 1.84 |
| MACD | 0.02 | 0.63 |
| Stochastic Oscillator | 51.85 | 87.14 |
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.